Cargando…

The association between the tumor immune microenvironments and clinical outcome in low‐grade, early‐stage endometrial cancer patients

Endometrial tumors show substantial heterogeneity in their immune microenvironment. This heterogeneity could be used to improve the accuracy of current outcome prediction tools. We assessed the immune microenvironment of 235 patients diagnosed with low‐grade, early‐stage endometrial cancer. Multiple...

Descripción completa

Detalles Bibliográficos
Autores principales: López‐Janeiro, Álvaro, Villalba‐Esparza, María, Brizzi, María Emilia, Jiménez‐Sánchez, Daniel, Ruz‐Caracuel, Ignacio, Kadioglu, Ece, Masetto, Ivan, Goubert, Virginie, Garcia‐Ros, David, Melero, Ignacio, Peláez‐García, Alberto, Hardisson, David, de Andrea, Carlos E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828119/
https://www.ncbi.nlm.nih.gov/pubmed/36169332
http://dx.doi.org/10.1002/path.6012
_version_ 1784867200136380416
author López‐Janeiro, Álvaro
Villalba‐Esparza, María
Brizzi, María Emilia
Jiménez‐Sánchez, Daniel
Ruz‐Caracuel, Ignacio
Kadioglu, Ece
Masetto, Ivan
Goubert, Virginie
Garcia‐Ros, David
Melero, Ignacio
Peláez‐García, Alberto
Hardisson, David
de Andrea, Carlos E
author_facet López‐Janeiro, Álvaro
Villalba‐Esparza, María
Brizzi, María Emilia
Jiménez‐Sánchez, Daniel
Ruz‐Caracuel, Ignacio
Kadioglu, Ece
Masetto, Ivan
Goubert, Virginie
Garcia‐Ros, David
Melero, Ignacio
Peláez‐García, Alberto
Hardisson, David
de Andrea, Carlos E
author_sort López‐Janeiro, Álvaro
collection PubMed
description Endometrial tumors show substantial heterogeneity in their immune microenvironment. This heterogeneity could be used to improve the accuracy of current outcome prediction tools. We assessed the immune microenvironment of 235 patients diagnosed with low‐grade, early‐stage endometrial cancer. Multiplex quantitative immunofluorescence was carried out to measure CD8, CD68, FOXP3, PD‐1, and PD‐L1 markers, as well as cytokeratin (CK), on tissue microarrays. Clustering results revealed five robust immune response patterns, each associated with specific immune populations, cell phenotypes, and cell spatial clustering. Most samples (69%) belonged to the immune‐desert subtype, characterized by low immune cell densities. Tumor‐infiltrating lymphocyte (TIL)‐rich samples (4%) displayed high CD8(+) T‐cell infiltration, as well as a high percentage of CD8/PD‐1(+) cells. Immune‐exclusion samples (19%) displayed the lowest CD8(+) infiltration combined with high PD‐L1 expression levels in CK(+) tumor cells. In addition, they demonstrated high tumor cell spatial clustering as well as increased spatial proximity of CD8(+)/PD‐1(+) and CK/PD‐L1(+) cells. FOXP3 and macrophage‐rich phenotypes (3% and 4% of total samples) displayed relatively high levels of FOXP3(+) regulatory T‐cells and CD68(+) macrophages, respectively. These phenotypes correlated with clinical outcomes, with immune‐exclusion tumors showing an association with tumor relapse. When compared with prediction models built using routine pathological variables, models optimized with immune variables showed increased outcome prediction capacity (AUC = 0.89 versus 0.78) and stratification potential. The improved prediction capacity was independent of mismatch repair protein status and adjuvant radiotherapy treatment. Further, immunofluorescence results could be partially recapitulated using single‐marker immunohistochemistry (IHC) performed on whole tissue sections. TIL‐rich tumors demonstrated increased CD8(+) T‐cells by IHC, while immune‐exclusion tumors displayed a lack of CD8(+) T‐cells and frequent expression of PD‐L1 in tumor cells. Our results demonstrate the capability of the immune microenvironment to improve standard prediction tools in low‐grade, early‐stage endometrial carcinomas. © 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
format Online
Article
Text
id pubmed-9828119
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley & Sons, Ltd
record_format MEDLINE/PubMed
spelling pubmed-98281192023-01-10 The association between the tumor immune microenvironments and clinical outcome in low‐grade, early‐stage endometrial cancer patients López‐Janeiro, Álvaro Villalba‐Esparza, María Brizzi, María Emilia Jiménez‐Sánchez, Daniel Ruz‐Caracuel, Ignacio Kadioglu, Ece Masetto, Ivan Goubert, Virginie Garcia‐Ros, David Melero, Ignacio Peláez‐García, Alberto Hardisson, David de Andrea, Carlos E J Pathol Original Articles Endometrial tumors show substantial heterogeneity in their immune microenvironment. This heterogeneity could be used to improve the accuracy of current outcome prediction tools. We assessed the immune microenvironment of 235 patients diagnosed with low‐grade, early‐stage endometrial cancer. Multiplex quantitative immunofluorescence was carried out to measure CD8, CD68, FOXP3, PD‐1, and PD‐L1 markers, as well as cytokeratin (CK), on tissue microarrays. Clustering results revealed five robust immune response patterns, each associated with specific immune populations, cell phenotypes, and cell spatial clustering. Most samples (69%) belonged to the immune‐desert subtype, characterized by low immune cell densities. Tumor‐infiltrating lymphocyte (TIL)‐rich samples (4%) displayed high CD8(+) T‐cell infiltration, as well as a high percentage of CD8/PD‐1(+) cells. Immune‐exclusion samples (19%) displayed the lowest CD8(+) infiltration combined with high PD‐L1 expression levels in CK(+) tumor cells. In addition, they demonstrated high tumor cell spatial clustering as well as increased spatial proximity of CD8(+)/PD‐1(+) and CK/PD‐L1(+) cells. FOXP3 and macrophage‐rich phenotypes (3% and 4% of total samples) displayed relatively high levels of FOXP3(+) regulatory T‐cells and CD68(+) macrophages, respectively. These phenotypes correlated with clinical outcomes, with immune‐exclusion tumors showing an association with tumor relapse. When compared with prediction models built using routine pathological variables, models optimized with immune variables showed increased outcome prediction capacity (AUC = 0.89 versus 0.78) and stratification potential. The improved prediction capacity was independent of mismatch repair protein status and adjuvant radiotherapy treatment. Further, immunofluorescence results could be partially recapitulated using single‐marker immunohistochemistry (IHC) performed on whole tissue sections. TIL‐rich tumors demonstrated increased CD8(+) T‐cells by IHC, while immune‐exclusion tumors displayed a lack of CD8(+) T‐cells and frequent expression of PD‐L1 in tumor cells. Our results demonstrate the capability of the immune microenvironment to improve standard prediction tools in low‐grade, early‐stage endometrial carcinomas. © 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland. John Wiley & Sons, Ltd 2022-10-25 2022-12 /pmc/articles/PMC9828119/ /pubmed/36169332 http://dx.doi.org/10.1002/path.6012 Text en © 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
López‐Janeiro, Álvaro
Villalba‐Esparza, María
Brizzi, María Emilia
Jiménez‐Sánchez, Daniel
Ruz‐Caracuel, Ignacio
Kadioglu, Ece
Masetto, Ivan
Goubert, Virginie
Garcia‐Ros, David
Melero, Ignacio
Peláez‐García, Alberto
Hardisson, David
de Andrea, Carlos E
The association between the tumor immune microenvironments and clinical outcome in low‐grade, early‐stage endometrial cancer patients
title The association between the tumor immune microenvironments and clinical outcome in low‐grade, early‐stage endometrial cancer patients
title_full The association between the tumor immune microenvironments and clinical outcome in low‐grade, early‐stage endometrial cancer patients
title_fullStr The association between the tumor immune microenvironments and clinical outcome in low‐grade, early‐stage endometrial cancer patients
title_full_unstemmed The association between the tumor immune microenvironments and clinical outcome in low‐grade, early‐stage endometrial cancer patients
title_short The association between the tumor immune microenvironments and clinical outcome in low‐grade, early‐stage endometrial cancer patients
title_sort association between the tumor immune microenvironments and clinical outcome in low‐grade, early‐stage endometrial cancer patients
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828119/
https://www.ncbi.nlm.nih.gov/pubmed/36169332
http://dx.doi.org/10.1002/path.6012
work_keys_str_mv AT lopezjaneiroalvaro theassociationbetweenthetumorimmunemicroenvironmentsandclinicaloutcomeinlowgradeearlystageendometrialcancerpatients
AT villalbaesparzamaria theassociationbetweenthetumorimmunemicroenvironmentsandclinicaloutcomeinlowgradeearlystageendometrialcancerpatients
AT brizzimariaemilia theassociationbetweenthetumorimmunemicroenvironmentsandclinicaloutcomeinlowgradeearlystageendometrialcancerpatients
AT jimenezsanchezdaniel theassociationbetweenthetumorimmunemicroenvironmentsandclinicaloutcomeinlowgradeearlystageendometrialcancerpatients
AT ruzcaracuelignacio theassociationbetweenthetumorimmunemicroenvironmentsandclinicaloutcomeinlowgradeearlystageendometrialcancerpatients
AT kadiogluece theassociationbetweenthetumorimmunemicroenvironmentsandclinicaloutcomeinlowgradeearlystageendometrialcancerpatients
AT masettoivan theassociationbetweenthetumorimmunemicroenvironmentsandclinicaloutcomeinlowgradeearlystageendometrialcancerpatients
AT goubertvirginie theassociationbetweenthetumorimmunemicroenvironmentsandclinicaloutcomeinlowgradeearlystageendometrialcancerpatients
AT garciarosdavid theassociationbetweenthetumorimmunemicroenvironmentsandclinicaloutcomeinlowgradeearlystageendometrialcancerpatients
AT meleroignacio theassociationbetweenthetumorimmunemicroenvironmentsandclinicaloutcomeinlowgradeearlystageendometrialcancerpatients
AT pelaezgarciaalberto theassociationbetweenthetumorimmunemicroenvironmentsandclinicaloutcomeinlowgradeearlystageendometrialcancerpatients
AT hardissondavid theassociationbetweenthetumorimmunemicroenvironmentsandclinicaloutcomeinlowgradeearlystageendometrialcancerpatients
AT deandreacarlose theassociationbetweenthetumorimmunemicroenvironmentsandclinicaloutcomeinlowgradeearlystageendometrialcancerpatients
AT lopezjaneiroalvaro associationbetweenthetumorimmunemicroenvironmentsandclinicaloutcomeinlowgradeearlystageendometrialcancerpatients
AT villalbaesparzamaria associationbetweenthetumorimmunemicroenvironmentsandclinicaloutcomeinlowgradeearlystageendometrialcancerpatients
AT brizzimariaemilia associationbetweenthetumorimmunemicroenvironmentsandclinicaloutcomeinlowgradeearlystageendometrialcancerpatients
AT jimenezsanchezdaniel associationbetweenthetumorimmunemicroenvironmentsandclinicaloutcomeinlowgradeearlystageendometrialcancerpatients
AT ruzcaracuelignacio associationbetweenthetumorimmunemicroenvironmentsandclinicaloutcomeinlowgradeearlystageendometrialcancerpatients
AT kadiogluece associationbetweenthetumorimmunemicroenvironmentsandclinicaloutcomeinlowgradeearlystageendometrialcancerpatients
AT masettoivan associationbetweenthetumorimmunemicroenvironmentsandclinicaloutcomeinlowgradeearlystageendometrialcancerpatients
AT goubertvirginie associationbetweenthetumorimmunemicroenvironmentsandclinicaloutcomeinlowgradeearlystageendometrialcancerpatients
AT garciarosdavid associationbetweenthetumorimmunemicroenvironmentsandclinicaloutcomeinlowgradeearlystageendometrialcancerpatients
AT meleroignacio associationbetweenthetumorimmunemicroenvironmentsandclinicaloutcomeinlowgradeearlystageendometrialcancerpatients
AT pelaezgarciaalberto associationbetweenthetumorimmunemicroenvironmentsandclinicaloutcomeinlowgradeearlystageendometrialcancerpatients
AT hardissondavid associationbetweenthetumorimmunemicroenvironmentsandclinicaloutcomeinlowgradeearlystageendometrialcancerpatients
AT deandreacarlose associationbetweenthetumorimmunemicroenvironmentsandclinicaloutcomeinlowgradeearlystageendometrialcancerpatients